Cargando…

Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus

Subjects with type 2 diabetes mellitus (T2D) are at increased risk for heart failure (HF). The cardiac-specific (FABP3) and adipose-tissue-specific (FABP4) types of the fatty acid binding proteins have been associated with both all-cause and cardiovascular (CV) mortality. The aim of this study was t...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez-Calvo, Ricardo, Granado-Casas, Minerva, Pérez-Montes de Oca, Alejandra, Julian, María Teresa, Domingo, Mar, Codina, Pau, Santiago-Vacas, Evelyn, Cediel, Germán, Julve, Josep, Rossell, Joana, Masana, Lluís, Mauricio, Didac, Lupón, Josep, Bayes-Genis, Antoni, Alonso, Núria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044995/
https://www.ncbi.nlm.nih.gov/pubmed/36978893
http://dx.doi.org/10.3390/antiox12030645
_version_ 1784913485920993280
author Rodríguez-Calvo, Ricardo
Granado-Casas, Minerva
Pérez-Montes de Oca, Alejandra
Julian, María Teresa
Domingo, Mar
Codina, Pau
Santiago-Vacas, Evelyn
Cediel, Germán
Julve, Josep
Rossell, Joana
Masana, Lluís
Mauricio, Didac
Lupón, Josep
Bayes-Genis, Antoni
Alonso, Núria
author_facet Rodríguez-Calvo, Ricardo
Granado-Casas, Minerva
Pérez-Montes de Oca, Alejandra
Julian, María Teresa
Domingo, Mar
Codina, Pau
Santiago-Vacas, Evelyn
Cediel, Germán
Julve, Josep
Rossell, Joana
Masana, Lluís
Mauricio, Didac
Lupón, Josep
Bayes-Genis, Antoni
Alonso, Núria
author_sort Rodríguez-Calvo, Ricardo
collection PubMed
description Subjects with type 2 diabetes mellitus (T2D) are at increased risk for heart failure (HF). The cardiac-specific (FABP3) and adipose-tissue-specific (FABP4) types of the fatty acid binding proteins have been associated with both all-cause and cardiovascular (CV) mortality. The aim of this study was to explore the prognosis value of FABP3 and FABP4 in ambulatory subjects with chronic HF (CHF), with and without T2D. A prospective study involving 240 ambulatory CHF subjects was performed. Patients were followed-up for a mean of 5.78 ± 3.30 years and cause of death (if any) was recorded. Primary endpoints were defined as all-cause and CV death, and a composite endpoint that included CV death or hospitalization for HF was included as a secondary endpoint. Baseline serum samples were obtained and the serum FABP3 and FABP4 concentrations were assessed by sandwich enzyme-linked immunosorbent assay. Survival analysis was performed with multivariable Cox regressions, using Fine and Gray competing risks models when needed, to explore the prognostic value of FABP3 and FABP4 concentrations, adjusting for potential confounders. Type 2 diabetes mellitus was highly prevalent, accounting for 47.5% for total subjects with CHF. Subjects with T2D showed higher mortality rates (T2D: 69.30%; non-T2D: 50.79%, p = 0.004) and higher serum FABP3 (1829.3 (1104.9–3440.5) pg/mL vs. 1396.05 (820.3–2362.16) pg/mL, p = 0.007) and FABP4 (45.5 (27.6–79.8) ng/mL vs. 34.1 (24.09–55.3) ng/mL, p = 0.006) concentrations compared with non-T2D CHF subjects. In the whole study cohort, FABP3 was independently associated with all-cause death, and both FABP3 and FABP4 concentrations were associated with CV mortality. The predictive values of these two molecules for all-cause (FABP3: HR 1.25, 95% CI 1.09–1.44; p = 0.002. FABP4: HR 2.21, 95% CI 1.12–4.36; p = 0.023) and CV mortality (FABP3: HR 1.28, 95% CI 1.09–1.50; p = 0.002. FABP4: HR 4.19, 95% CI 2.21–7.95; p < 0.001) were only statistically significant in the subgroup of subjects with T2D. Notably, FABP4 (HR 2.07, 95% CI 1.11–3.87; p = 0.022), but not FABP3, also predicted the occurrence of the composite endpoint (death or hospitalization for HF) only in subjects with T2D. All these associations were not found in CHF subjects without T2D. Our findings support the usefulness of serum FABP3 and FABP4 concentrations as independent predictors for the occurrence of all-cause and CV mortality in ambulatory subjects with CHF with T2D.
format Online
Article
Text
id pubmed-10044995
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100449952023-03-29 Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus Rodríguez-Calvo, Ricardo Granado-Casas, Minerva Pérez-Montes de Oca, Alejandra Julian, María Teresa Domingo, Mar Codina, Pau Santiago-Vacas, Evelyn Cediel, Germán Julve, Josep Rossell, Joana Masana, Lluís Mauricio, Didac Lupón, Josep Bayes-Genis, Antoni Alonso, Núria Antioxidants (Basel) Article Subjects with type 2 diabetes mellitus (T2D) are at increased risk for heart failure (HF). The cardiac-specific (FABP3) and adipose-tissue-specific (FABP4) types of the fatty acid binding proteins have been associated with both all-cause and cardiovascular (CV) mortality. The aim of this study was to explore the prognosis value of FABP3 and FABP4 in ambulatory subjects with chronic HF (CHF), with and without T2D. A prospective study involving 240 ambulatory CHF subjects was performed. Patients were followed-up for a mean of 5.78 ± 3.30 years and cause of death (if any) was recorded. Primary endpoints were defined as all-cause and CV death, and a composite endpoint that included CV death or hospitalization for HF was included as a secondary endpoint. Baseline serum samples were obtained and the serum FABP3 and FABP4 concentrations were assessed by sandwich enzyme-linked immunosorbent assay. Survival analysis was performed with multivariable Cox regressions, using Fine and Gray competing risks models when needed, to explore the prognostic value of FABP3 and FABP4 concentrations, adjusting for potential confounders. Type 2 diabetes mellitus was highly prevalent, accounting for 47.5% for total subjects with CHF. Subjects with T2D showed higher mortality rates (T2D: 69.30%; non-T2D: 50.79%, p = 0.004) and higher serum FABP3 (1829.3 (1104.9–3440.5) pg/mL vs. 1396.05 (820.3–2362.16) pg/mL, p = 0.007) and FABP4 (45.5 (27.6–79.8) ng/mL vs. 34.1 (24.09–55.3) ng/mL, p = 0.006) concentrations compared with non-T2D CHF subjects. In the whole study cohort, FABP3 was independently associated with all-cause death, and both FABP3 and FABP4 concentrations were associated with CV mortality. The predictive values of these two molecules for all-cause (FABP3: HR 1.25, 95% CI 1.09–1.44; p = 0.002. FABP4: HR 2.21, 95% CI 1.12–4.36; p = 0.023) and CV mortality (FABP3: HR 1.28, 95% CI 1.09–1.50; p = 0.002. FABP4: HR 4.19, 95% CI 2.21–7.95; p < 0.001) were only statistically significant in the subgroup of subjects with T2D. Notably, FABP4 (HR 2.07, 95% CI 1.11–3.87; p = 0.022), but not FABP3, also predicted the occurrence of the composite endpoint (death or hospitalization for HF) only in subjects with T2D. All these associations were not found in CHF subjects without T2D. Our findings support the usefulness of serum FABP3 and FABP4 concentrations as independent predictors for the occurrence of all-cause and CV mortality in ambulatory subjects with CHF with T2D. MDPI 2023-03-04 /pmc/articles/PMC10044995/ /pubmed/36978893 http://dx.doi.org/10.3390/antiox12030645 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rodríguez-Calvo, Ricardo
Granado-Casas, Minerva
Pérez-Montes de Oca, Alejandra
Julian, María Teresa
Domingo, Mar
Codina, Pau
Santiago-Vacas, Evelyn
Cediel, Germán
Julve, Josep
Rossell, Joana
Masana, Lluís
Mauricio, Didac
Lupón, Josep
Bayes-Genis, Antoni
Alonso, Núria
Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus
title Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus
title_full Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus
title_fullStr Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus
title_full_unstemmed Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus
title_short Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus
title_sort fatty acid binding proteins 3 and 4 predict both all-cause and cardiovascular mortality in subjects with chronic heart failure and type 2 diabetes mellitus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044995/
https://www.ncbi.nlm.nih.gov/pubmed/36978893
http://dx.doi.org/10.3390/antiox12030645
work_keys_str_mv AT rodriguezcalvoricardo fattyacidbindingproteins3and4predictbothallcauseandcardiovascularmortalityinsubjectswithchronicheartfailureandtype2diabetesmellitus
AT granadocasasminerva fattyacidbindingproteins3and4predictbothallcauseandcardiovascularmortalityinsubjectswithchronicheartfailureandtype2diabetesmellitus
AT perezmontesdeocaalejandra fattyacidbindingproteins3and4predictbothallcauseandcardiovascularmortalityinsubjectswithchronicheartfailureandtype2diabetesmellitus
AT julianmariateresa fattyacidbindingproteins3and4predictbothallcauseandcardiovascularmortalityinsubjectswithchronicheartfailureandtype2diabetesmellitus
AT domingomar fattyacidbindingproteins3and4predictbothallcauseandcardiovascularmortalityinsubjectswithchronicheartfailureandtype2diabetesmellitus
AT codinapau fattyacidbindingproteins3and4predictbothallcauseandcardiovascularmortalityinsubjectswithchronicheartfailureandtype2diabetesmellitus
AT santiagovacasevelyn fattyacidbindingproteins3and4predictbothallcauseandcardiovascularmortalityinsubjectswithchronicheartfailureandtype2diabetesmellitus
AT cedielgerman fattyacidbindingproteins3and4predictbothallcauseandcardiovascularmortalityinsubjectswithchronicheartfailureandtype2diabetesmellitus
AT julvejosep fattyacidbindingproteins3and4predictbothallcauseandcardiovascularmortalityinsubjectswithchronicheartfailureandtype2diabetesmellitus
AT rosselljoana fattyacidbindingproteins3and4predictbothallcauseandcardiovascularmortalityinsubjectswithchronicheartfailureandtype2diabetesmellitus
AT masanalluis fattyacidbindingproteins3and4predictbothallcauseandcardiovascularmortalityinsubjectswithchronicheartfailureandtype2diabetesmellitus
AT mauriciodidac fattyacidbindingproteins3and4predictbothallcauseandcardiovascularmortalityinsubjectswithchronicheartfailureandtype2diabetesmellitus
AT luponjosep fattyacidbindingproteins3and4predictbothallcauseandcardiovascularmortalityinsubjectswithchronicheartfailureandtype2diabetesmellitus
AT bayesgenisantoni fattyacidbindingproteins3and4predictbothallcauseandcardiovascularmortalityinsubjectswithchronicheartfailureandtype2diabetesmellitus
AT alonsonuria fattyacidbindingproteins3and4predictbothallcauseandcardiovascularmortalityinsubjectswithchronicheartfailureandtype2diabetesmellitus